National Institutes of Health to Grant Exclusive License for Melanoma Antigens to Therion Biologics Corporation

Summary

The National Institutes of Health is considering granting an exclusive worldwide license to Therion Biologics Corporation to use melanoma antigens in diagnostic and therapeutic methods, with the potential to treat and prevent human cancer using recombinant poxviruses.